Key strengths include a focused biosimilar strategy, strong gross margins, and a sophisticated, vertically integrated manufacturing platform that can underpin cost advantages. The company already has meaningful revenue and positive operating profit, supported by global partnerships with established pharmaceutical players for commercialization. Its robust and diversified pipeline of biosimilar candidates, combined with deep in‑house technical expertise and modern facilities, provides multiple avenues for future growth. Short‑term liquidity is acceptable, with adequate cash and current assets to support ongoing operations and development work.

The most prominent risks are financial and execution‑related. High leverage, large net debt, and negative shareholder equity point to a stretched balance sheet and heightened sensitivity to any operational or regulatory setbacks. Cash flows from operations are negative, and free cash flow is deeply negative, leaving the company dependent on external financing to fund both its pipeline and capital expenditures. On the business side, Alvotech faces fierce competition, regulatory uncertainty, pricing pressure, and complex patent landscapes in each target market. Any delays in approvals, manufacturing issues, or weaker‑than‑expected uptake of key products could challenge both growth plans and the company’s ability to manage its debt load.

Looking ahead, Alvotech’s outlook is highly levered to successful execution of its biosimilar pipeline and commercialization strategy. If upcoming launches scale as planned, the existing infrastructure and strong gross margins could translate into improving cash generation and a gradual strengthening of the balance sheet. However, the path is inherently uncertain due to regulatory, competitive, and funding risks, especially given the current negative equity and reliance on external capital. Overall, the company combines substantial strategic and technological promise with a capital structure and cash profile that require careful monitoring and successful delivery on its growth agenda to remain sustainable over the long term.